204 related articles for article (PubMed ID: 28188806)
1. Role of CCL20 mediated immune cell recruitment in NF-κB mediated TRAIL resistance of pancreatic cancer.
Geismann C; Grohmann F; Dreher A; Häsler R; Rosenstiel P; Legler K; Hauser C; Egberts JH; Sipos B; Schreiber S; Linkermann A; Hassan Z; Schneider G; Schäfer H; Arlt A
Biochim Biophys Acta Mol Cell Res; 2017 May; 1864(5):782-796. PubMed ID: 28188806
[TBL] [Abstract][Full Text] [Related]
2. c-Rel is a critical mediator of NF-κB-dependent TRAIL resistance of pancreatic cancer cells.
Geismann C; Grohmann F; Sebens S; Wirths G; Dreher A; Häsler R; Rosenstiel P; Hauser C; Egberts JH; Trauzold A; Schneider G; Sipos B; Zeissig S; Schreiber S; Schäfer H; Arlt A
Cell Death Dis; 2014 Oct; 5(10):e1455. PubMed ID: 25299780
[TBL] [Abstract][Full Text] [Related]
3. NF-κB/RelA controlled A20 limits TRAIL-induced apoptosis in pancreatic cancer.
Geismann C; Hauser C; Grohmann F; Schneeweis C; Bölter N; Gundlach JP; Schneider G; Röcken C; Meinhardt C; Schäfer H; Schreiber S; Arlt A
Cell Death Dis; 2023 Jan; 14(1):3. PubMed ID: 36596765
[TBL] [Abstract][Full Text] [Related]
4. TRAIL/NF-κB/CX3CL1 Mediated Onco-Immuno Crosstalk Leading to TRAIL Resistance of Pancreatic Cancer Cell Lines.
Geismann C; Erhart W; Grohmann F; Schreiber S; Schneider G; Schäfer H; Arlt A
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29867042
[TBL] [Abstract][Full Text] [Related]
5. CCL20 is elevated during obesity and differentially regulated by NF-κB subunits in pancreatic β-cells.
Burke SJ; Karlstad MD; Regal KM; Sparer TE; Lu D; Elks CM; Grant RW; Stephens JM; Burk DH; Collier JJ
Biochim Biophys Acta; 2015 Jun; 1849(6):637-52. PubMed ID: 25882704
[TBL] [Abstract][Full Text] [Related]
6. SKP2 confers resistance of pancreatic cancer cells towards TRAIL-induced apoptosis.
Schüler S; Diersch S; Hamacher R; Schmid RM; Saur D; Schneider G
Int J Oncol; 2011 Jan; 38(1):219-25. PubMed ID: 21109943
[TBL] [Abstract][Full Text] [Related]
7. Advancement of NF-κB Signaling Pathway: A Novel Target in Pancreatic Cancer.
Pramanik KC; Makena MR; Bhowmick K; Pandey MK
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30563089
[TBL] [Abstract][Full Text] [Related]
8. The therapeutic targeting of the FGFR1/Src/NF-κB signaling axis inhibits pancreatic ductal adenocarcinoma stemness and oncogenicity.
Lai SW; Bamodu OA; Tsai WC; Chang YM; Lee WH; Yeh CT; Chao TY
Clin Exp Metastasis; 2018 Oct; 35(7):663-677. PubMed ID: 29987671
[TBL] [Abstract][Full Text] [Related]
9. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo.
Vogler M; Walczak H; Stadel D; Haas TL; Genze F; Jovanovic M; Gschwend JE; Simmet T; Debatin KM; Fulda S
Cancer Res; 2008 Oct; 68(19):7956-65. PubMed ID: 18829553
[TBL] [Abstract][Full Text] [Related]
10. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling.
Chen X; Kandasamy K; Srivastava RK
Cancer Res; 2003 Mar; 63(5):1059-66. PubMed ID: 12615723
[TBL] [Abstract][Full Text] [Related]
11. The novel TRAIL-receptor agonist APG350 exerts superior therapeutic activity in pancreatic cancer cells.
Legler K; Hauser C; Egberts JH; Willms A; Heneweer C; Boretius S; Röcken C; Glüer CC; Becker T; Kluge M; Hill O; Gieffers C; Fricke H; Kalthoff H; Lemke J; Trauzold A
Cell Death Dis; 2018 May; 9(5):445. PubMed ID: 29670075
[TBL] [Abstract][Full Text] [Related]
12. Metallothionein-1G suppresses pancreatic cancer cell stemness by limiting activin A secretion
Li K; Zhang Z; Mei Y; Yang Q; Qiao S; Ni C; Yao Y; Li X; Li M; Wei D; Fu W; Guo X; Huang X; Yang H
Theranostics; 2021; 11(7):3196-3212. PubMed ID: 33537082
[TBL] [Abstract][Full Text] [Related]
13. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
Hari Y; Harashima N; Tajima Y; Harada M
Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
[TBL] [Abstract][Full Text] [Related]
14. Mutations in K-Ras linked to levels of osteoprotegerin and sensitivity to TRAIL-induced cell death in pancreatic ductal adenocarcinoma cells.
Kanzaki H; Ohtaki A; Merchant FK; Greene MI; Murali R
Exp Mol Pathol; 2013 Apr; 94(2):372-9. PubMed ID: 23219833
[TBL] [Abstract][Full Text] [Related]
15. Cancer-FOXP3 directly activated CCL5 to recruit FOXP3
Wang X; Lang M; Zhao T; Feng X; Zheng C; Huang C; Hao J; Dong J; Luo L; Li X; Lan C; Yu W; Yu M; Yang S; Ren H
Oncogene; 2017 May; 36(21):3048-3058. PubMed ID: 27991933
[TBL] [Abstract][Full Text] [Related]
16. Hyper-O-GlcNAcylation is anti-apoptotic and maintains constitutive NF-κB activity in pancreatic cancer cells.
Ma Z; Vocadlo DJ; Vosseller K
J Biol Chem; 2013 May; 288(21):15121-30. PubMed ID: 23592772
[TBL] [Abstract][Full Text] [Related]
17. TRAIL Promotes Tumor Growth in a Syngeneic Murine Orthotopic Pancreatic Cancer Model and Affects the Host Immune Response.
Beyer K; Normann L; Sendler M; Käding A; Heidecke CD; Partecke LI; von Bernstorff W
Pancreas; 2016 Mar; 45(3):401-8. PubMed ID: 26390425
[TBL] [Abstract][Full Text] [Related]
18. Critical link between TRAIL and CCL20 for the activation of TH2 cells and the expression of allergic airway disease.
Weckmann M; Collison A; Simpson JL; Kopp MV; Wark PA; Smyth MJ; Yagita H; Matthaei KI; Hansbro N; Whitehead B; Gibson PG; Foster PS; Mattes J
Nat Med; 2007 Nov; 13(11):1308-15. PubMed ID: 17934471
[TBL] [Abstract][Full Text] [Related]
19. SERP1 is a novel marker of poor prognosis in pancreatic ductal adenocarcinoma patients via anti-apoptosis and regulating SRPRB/NF-κB axis.
Ma Q; Wu X; Wu J; Liang Z; Liu T
Int J Oncol; 2017 Oct; 51(4):1104-1114. PubMed ID: 28902358
[TBL] [Abstract][Full Text] [Related]
20. The anti-CD20 mAb LFB-R603 interrupts the dysregulated NF-κB/Snail/RKIP/PTEN resistance loop in B-NHL cells: role in sensitization to TRAIL apoptosis.
Baritaki S; Militello L; Malaponte G; Spandidos DA; Salcedo M; Bonavida B
Int J Oncol; 2011 Jun; 38(6):1683-94. PubMed ID: 21455568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
